


Express Mail No.: EL 501 637 659 US



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	9632-012	09/724,530
	APPLICANT	
	Siegall <i>et al.</i>	
	FILING DATE	GROUP
	November 28, 2000	1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	CF	Ghetie et al., 1990, "Disseminated or Localized Growth of a Human B-Cell Tumor (Daudi) in Scid Mice", Int. J. Cancer 45:481-485.
	CG	Kawata et al., 1994, "Establishment of New SCID and Nude Mouse Models of Human B-Leukemia/Lymphoma and Effective Therapy of the Tumors with Immunotoxin and Monoclonal Antibody: Marked Difference between the SCID and Nude Mouse Models in the Antitumor Efficacy of Monoclonal Antibody", Cancer Research 54: 2688-2694.
	CH	Cattan and Douglas, 1994, "The C.B. 17 Scid Mouse Strain as a Model for Human Disseminated Leukaemia and Myeloma <i>in Vivo</i> ", Leukemia Research 18:513-522.
	CI	Buchsbaum et al., 1992, "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody", Cancer Research 52:637-642.
	CJ	Kaminsky et al., 2001, "Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade of Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas", J. of Clinical Oncology 19:3918-3928.
	CK	Ostrowski <i>et al.</i> , 2001, "Inhibition of Angiogenesis in the Treatment of Tumors", Archivum Immunologiae et Therapiae Experimentalis 49:27-31.
✓	CL	Pound et al., 1998, "Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells", Int'l Immunology 11:11-20.
KAC	CM	Hirano et al., 1999, "Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand", Blood 93(9):2999-3007

EXAMINER <i>Karen A. Garella</i>	DATE CONSIDERED
----------------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAR 04 2007
TECH CENT